
United Therapeutics Corporation: updates and filings
Price
$559.10
November 19, 2026Market cap $24.5B
What Ploutos Investor adds for United Therapeutics
Part of Ploutos Investor, €9.99 a month
- The full history: 17 fiscal years, from 2009
- The estimated fair value, with its range and its certainty
- The full analysis, 18 a month
- More questions to the chat on its filings
- Excel with every year
- An email when it reports, changes its dividend or an officer buys
Sign in with a free account to see the last 5 fiscal years.
Notes on these figures
- The filings show substantial debt that is not stated in a form we can read. The debt, net cash, enterprise value, the multiples built on it and the return on invested capital would leave that debt out, so we leave them out.
What comes next, and what happened
Its next results and latest dividend, and the filings that told of something: results, deals, people, debt. In plain words, each linked to the filing.
Next results
last Nov 4, 2026next Feb 4, 2027
An estimate from when it has reported before, which has been regular. The company announces the date itself.
November 2026
August 2026
May 2026
March 2026
Its SEC filings
What it has filed lately, newest first, linked to the document itself.
- Nov 4, 2026Over-5% holder statement (passive) (amendment)FormSCHEDULE 13G/A
- Nov 4, 2026Results of operationsForm8-K
- Nov 4, 2026Quarterly reportfor the period to Sep 30, 2026Form10-Q
- Oct 22, 2026Other material eventsForm8-K
- Oct 14, 2026Other material eventsForm8-K
- Sep 8, 2026Material agreement entered, Regulation FD disclosureForm8-K
- Aug 14, 2026Over-5% holder statement (passive) (amendment)FormSCHEDULE 13G/A
- Aug 13, 2026Over-5% holder statement (passive) (amendment)FormSCHEDULE 13G/A
- Aug 5, 2026Results of operationsForm8-K
- Aug 5, 2026Quarterly reportfor the period to Jun 30, 2026Form10-Q
- Jul 23, 2026Officer or director change, Regulation FD disclosureForm8-K
- Jul 13, 2026FilingFormS-8 POS
- Jul 13, 2026FilingFormS-8 POS
- Jul 13, 2026FilingFormS-8 POS
- Jul 13, 2026FilingFormS-8 POS
- Jul 13, 2026FilingFormS-8 POS
- Jul 13, 2026FilingFormS-8 POS
- Jul 13, 2026FilingFormS-8 POS
- Jul 13, 2026FilingFormS-8 POS
- Jul 13, 2026FilingFormS-8 POS
- Jul 13, 2026Shares registered for employeesFormS-8
- Jun 29, 2026Officer or director change, shareholder voteForm8-K
- Jun 2, 2026Conflict minerals reportFormSD
- May 6, 2026Results of operationsForm8-K
- May 6, 2026Quarterly reportfor the period to Mar 31, 2026Form10-Q
| Filed | Form | What it is | Filing |
|---|---|---|---|
| Nov 4, 2026 | SCHEDULE 13G/A | Over-5% holder statement (passive) (amendment) | Document |
| Nov 4, 2026 | 8-K | Results of operations | Document |
| Nov 4, 2026 | 10-Q | Quarterly reportfor the period to Sep 30, 2026 | Document |
| Oct 22, 2026 | 8-K | Other material events | Document |
| Oct 14, 2026 | 8-K | Other material events | Document |
| Sep 8, 2026 | 8-K | Material agreement entered, Regulation FD disclosure | Document |
| Aug 14, 2026 | SCHEDULE 13G/A | Over-5% holder statement (passive) (amendment) | Document |
| Aug 13, 2026 | SCHEDULE 13G/A | Over-5% holder statement (passive) (amendment) | Document |
| Aug 5, 2026 | 8-K | Results of operations | Document |
| Aug 5, 2026 | 10-Q | Quarterly reportfor the period to Jun 30, 2026 | Document |
| Jul 23, 2026 | 8-K | Officer or director change, Regulation FD disclosure | Document |
| Jul 13, 2026 | S-8 POS | Filing | Document |
| Jul 13, 2026 | S-8 POS | Filing | Document |
| Jul 13, 2026 | S-8 POS | Filing | Document |
| Jul 13, 2026 | S-8 POS | Filing | Document |
| Jul 13, 2026 | S-8 POS | Filing | Document |
| Jul 13, 2026 | S-8 POS | Filing | Document |
| Jul 13, 2026 | S-8 POS | Filing | Document |
| Jul 13, 2026 | S-8 POS | Filing | Document |
| Jul 13, 2026 | S-8 POS | Filing | Document |
| Jul 13, 2026 | S-8 | Shares registered for employees | Document |
| Jun 29, 2026 | 8-K | Officer or director change, shareholder vote | Document |
| Jun 2, 2026 | SD | Conflict minerals report | Document |
| May 6, 2026 | 8-K | Results of operations | Document |
| May 6, 2026 | 10-Q | Quarterly reportfor the period to Mar 31, 2026 | Document |
From the company's record at the SEC (EDGAR). The topics of each 8-K are the item codes the company itself filed. Its whole record at the SEC since Apr 16, 1999: every report, 8-K, meeting and letter. Of its other filings (901 in all), the newest.
The full analysis
What do United Therapeutics's filings show?
The filings are where every one of United Therapeutics's figures comes from. The full Ploutos AI analysis reads everything the company has filed and shows what stands behind it, with a source for every figure.
- A fair value range built from the filings
- Earnings quality, debt and red flags
- Insider and institutional moves
- The case for and the case against
Related pages
The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.
The figures come from the company's SEC filings and the share price, and describe what it has reported. They are not a score or a fair value.